On 9th April
2018, the Scottish Medicines Consortium (SMC) published its decision to
recommend dimeythl fumarate (Skilarence) for the treatment of severe
psoriasis in Scotland.
(Skilarence) is recommended to treat severe psoriasis, where people have not
had adequate results from conventional systemic treatments, or cannot take them.
Some people with
psoriasis may be aware of a similar treatment, known as Fumaderm or Fumaric
Acid Esters. This is a German treatment that is not licensed in the UK, but has
sometimes been prescribed on a case-by-case basis. Dimethyl fumarate
(Skilarence) is licensed in the UK, and uses the main active ingredient from
Today’s SMC recommendation, along with NICE’s
positive recommendation for England and Wales last year, should make fumaric
acid ester treatment more accessible to people with psoriasis in the UK.
You can read more about